Autoimmune Market Forecast to 2014

The autoimmune market is proving that the era of the blockbuster is not dead.

Of 14 brands already at or expected to reach blockbuster status, half generate at least $3 billion annually. Nine mid-level products will generate $400 million, at minimum, by 2014. For autoimmune drugs, reaching blockbuster-level success is an expectation as much as a goal.

Whether you' re exploring your options or need to increase your presence in the market, autoimmune compounds provide lucrative opportunities -- don' t miss out!

From sales projections to clinical trial data to analysts' insights, Autoimmune Market Forecast to 2014 tells you everything you need to know. Unlike other market forecast reports out there, ours covers all of the major indications - rheumatoid arthritis, ulcerative colitis, Crohn' s disease, multiple sclerosis, psoriasis and lupus - profiling 40+ drugs and nine leading autoimmune product manufacturers.

Delve into the data to:

• Learn how brands and drug classes have fared: where they' ve succeeded - and failed
• Show solid, objective evidence for your decision-making
• Keep track of the competition
• Get the latest on clinical trials
• Uncover potential business development opportunities

Cutting Edge Information analysts gathered data from primary and secondary sources to develop this report. Sources include interviews with key executives; company publications, news releases and government filings; industry analyst publications and forecasts; US and European government documents clinical development and sales databases,including BioPharm lnsight; patientadvocacy groups; industry periodicals; and othersources.

All meta-analyses of companies, drug classes and indications are built upon and limited to the drugs profiled within the report.